Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the "AMF") has approved a prospectus under no. 24-432, on Octo ...

A downtrend has been apparent in Inventiva S.A. Sponsored ADR (IVA) lately with too much selling pressure. The stock has declined 17.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial. Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial. Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarker ...

Cash: € 285,764.46 Number of shares: 129,659 Number of executions on buy side on semester: 1,886 Number of executions on sell side on semester: 1,610 Traded volume on buy side on semester: 322,578 shares for € 1,074,534.26 Traded volume on sell side on semester: 276,147 shares for € 938,985.90 When the contract was initially implemented, the following resources were included in the liquidity account: | --- | --- | --- | --- | --- | --- | |-----------------|--------|-----------|-------|-------|-----------| | ...

The Company intends to use approximately 95% of the net proceeds from the Transaction to continue the NATiV3 Phase III trial of lanifibranor in MASH/ NASH ("NATiV3") and the remainder for general corporate purposes. The Royalty Certificates are being issued pursuant to a decision of Board of Directors on July 16, 2024, in accordance with the provisions of Article L. 228-36-A of the French Commercial Code (Code de commerce) to one new investor and existing shareholders. The holders of Royalty Certificates ar ...

Group 1 - The stock of Inventiva S.A. Sponsored ADR (IVA) has experienced a significant downtrend, declining 28% over the past four weeks due to excessive selling pressure [1] - The stock is currently in oversold territory, indicated by an RSI reading of 28.42, suggesting a potential trend reversal [2][3] - Analysts have raised earnings estimates for IVA by 0.5% over the last 30 days, indicating a consensus that the company may report better earnings than previously predicted [3] Group 2 - The Zacks Rank for IVA is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [3]

Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non- alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced that two scientific abstracts have been selected for poster presentation at the upc ...

Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, reported its financial results for Q1 2024, highlighting significant cash usage in operations and R&D, while also providing updates on its clinical trials and corporate governance [1][7]. Financial Results - As of March 31, 2024, the company's cash and cash equivalents were €11.0 million, down from €26.9 million at the end of 2023. Short-term deposits were €0.1 million, and long-term deposits were €19.0 million [2][10]. - Net cash used in operating activities for Q1 2024 was (€29.4) million, an increase from (€20.4) million in Q1 2023. R&D expenses rose by 82% year-over-year, driven by costs related to the NATiV3 Phase III clinical trial [3]. - Net cash used in investing activities was (€10.3) million in Q1 2024, compared to (€8.4) million in Q1 2023, primarily due to changes in deposits [4]. - The company generated €23.7 million in financing activities during Q1 2024, a significant increase from (€1.2) million in Q1 2023, attributed to a €25 million loan from the European Investment Bank [5]. Corporate Update - The company appointed Andre Turenne to its Board of Directors, pending shareholder ratification [9][11]. - The NATiV3 Phase III clinical trial for lanifibranor continues without protocol modifications, with 280 sites in 15 countries resuming patient screening [10][20]. - The anticipated last patient first visit for the NATiV3 trial is targeted for the first half of 2024 [12]. Research and Development - Inventiva's lead product candidate, lanifibranor, is in a pivotal Phase III trial for MASH/NASH, a chronic liver disease with no approved therapies [17]. - The company has suspended clinical efforts for odiparcil to focus on lanifibranor and is reviewing options for its further development [18]. - The company has a robust scientific team and an extensive library of approximately 240,000 pharmacologically relevant molecules [19].

Core Viewpoint - The Data Monitoring Committee (DMC) has recommended the continuation of the NATiV3 Phase III clinical trial for lanifibranor without modifications, confirming its good safety profile based on a review of safety data from over 900 patients [1][2][3]. Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and other diseases with significant unmet medical needs [2][8]. - The company is advancing its lead product candidate, lanifibranor, which is a pan-PPAR agonist designed to target all three PPAR isoforms, contributing to its favorable tolerability profile observed in clinical trials [4][9]. Clinical Trial Details - The NATiV3 trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of lanifibranor in adult patients with biopsy-proven non-cirrhotic MASH/NASH and F2/F3 liver fibrosis, involving approximately 900 patients over a 72-week period [5][6]. - The DMC's review included safety data from more than 900 patients, with over 360 treated for more than 48 weeks and 80 for more than 72 weeks, supporting the trial's continuation [3][5]. Regulatory Status - Lanifibranor has received Breakthrough Therapy and Fast Track designations from the FDA for the treatment of MASH/NASH, which may expedite its development and review process [4][8].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...